Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

645 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.
Windyga J, Lissitchkov T, Stasyshyn O, Mamonov V, Rusen L, Lamas JL, Oh MS, Chapman M, Fritsch S, Pavlova BG, Wong WY, Abbuehl BE. Windyga J, et al. Among authors: oh ms. Haemophilia. 2014 Jan;20(1):15-24. doi: 10.1111/hae.12228. Epub 2013 Jul 9. Haemophilia. 2014. PMID: 23834666 Clinical Trial.
Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326).
Solano Trujillo MH, Stasyshyn O, Rusen L, Serban M, Lamas JL, Perina FG, Urasinski T, Oh M, Knowlton WB, Valenta-Singer B, Pavlova BG, Abbuehl B. Solano Trujillo MH, et al. Haemophilia. 2014 Sep;20(5):674-81. doi: 10.1111/hae.12444. Epub 2014 Apr 10. Haemophilia. 2014. PMID: 24720694 Clinical Trial.
Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens.
Collins PW, Björkman S, Fischer K, Blanchette V, Oh M, Schroth P, Fritsch S, Casey K, Spotts G, Ewenstein BM. Collins PW, et al. J Thromb Haemost. 2010 Feb;8(2):269-75. doi: 10.1111/j.1538-7836.2009.03703.x. Epub 2009 Nov 23. J Thromb Haemost. 2010. PMID: 19943875 Free article.
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A.
Collins PW, Blanchette VS, Fischer K, Björkman S, Oh M, Fritsch S, Schroth P, Spotts G, Astermark J, Ewenstein B; rAHF-PFM Study Group. Collins PW, et al. J Thromb Haemost. 2009 Mar;7(3):413-20. doi: 10.1111/j.1538-7836.2008.03270.x. Epub 2008 Dec 20. J Thromb Haemost. 2009. PMID: 19143924 Free article. Clinical Trial.
Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.
Björkman S, Blanchette VS, Fischer K, Oh M, Spotts G, Schroth P, Fritsch S, Patrone L, Ewenstein BM; Advate Clinical Program Group; Collins PW. Björkman S, et al. J Thromb Haemost. 2010 Apr;8(4):730-6. doi: 10.1111/j.1538-7836.2010.03757.x. J Thromb Haemost. 2010. PMID: 20398185 Free PMC article.
Influence of prestroke glycemic status on outcomes by age in patients with acute ischemic stroke and diabetes mellitus.
Kim JT, Lee JS, Kim H, Kim BJ, Kang J, Lee KJ, Park JM, Kang K, Lee SJ, Kim JG, Cha JK, Kim DH, Park TH, Lee K, Lee J, Hong KS, Cho YJ, Park HK, Lee BC, Yu KH, Oh MS, Kim DE, Choi JC, Kwon JH, Kim WJ, Shin DI, Yum KS, Sohn SI, Hong JH, Lee SH, Kim C, Park MS, Ryu WS, Park KY, Lee J, Saver JL, Bae HJ. Kim JT, et al. Among authors: oh ms. Eur J Neurol. 2025 Jan;32(1):e70004. doi: 10.1111/ene.70004. Eur J Neurol. 2025. PMID: 39714194 Free PMC article.
645 results